Introduction E-twenty-six (ETS) specific transcription factors are a family of Ͼ 20 helix-loop-helix domain transcription factors that have been implicated in a myriad of cellular processes, including hematopoiesis. 1 The hallmark ETS factor protein involved in hematopoietic development is SPI1 (Spleen focus forming virus Proviral Integration site 1; PU.1), which activates gene expression during myeloid and B-lymphoid cell development. Other ETS factors include the 2 closely related transcriptional activator proteins ERG (Ets Related Gene) and FLI1 (Friend Leukemia virus Integration site 1), which both play crucial roles in hematopoietic development 2,3 and multiple forms of cancer. 4,5 Recently, SPI1 was identified as a binding partner of the PML-RAR-␣ oncofusion protein complex in an inducible overexpression model. 6 The PML-RAR-␣ oncofusion protein is the result of a translocation t(15;17)(q22;q21) involving the promyelocytic leukemia (PML) gene on chromosome 15 and the retinoic acid receptor-␣ (RAR-␣) on chromosome 17. 7,8 Another translocation, t(8;21)(q22;q22), is present in ϳ 10% of all de novo acute myeloid leukemia (AML) cases, and results in the expression of the AML1-ETO (RUNX1-RUNX1T1) oncofusion protein. Expression of the AML1-ETO oncofusion protein in hematopoietic cells results in a stage-specific arrest of maturation and increased cell survival, predisposing cells to develop leukemia. 9 At the molecular level RUNX1 (Runt-related transcription factor 1; AML1, CBFA2) represents a DNA-binding transcriptional activator factor required for hematopoiesis, 10,11 while ETO (eight-twenty-one; MTG8, RUNX1T1) acts as a corepressor molecule. 12 The t(8;21) translocation replaces the transactivation domain of RUNX1/AML1 with the almost complete ETO protein, thereby converting an essential transcriptional activator into a strong repressor. 13,14 Here we extend genome-wide AML1-ETO studies 15,16 and reveal that a subset of AML1-ETO binding sites are bound by CBF- (core binding factor-), whereas nearly all are bound by HEB (HeLa E-box-binding factor), RUNX1/AML1 as well as by the ETS factors ERG and FLI1. Subsequent analysis in t(8;21) cells revealed cell type specific ETS factor binding and preferential AML1-ETO binding to the cell type specific ETS factor binding sites, suggesting that these proteins facilitate oncofusion protein binding. In addition, we uncovered that binding of the ETS factors correlates with the "active" histone acetylation mark. Together, our results suggest that ETS factors demarcate hematopoietic regulatory sites that provide a target for (aberrant) epigenetic regulation by oncofusion proteins.
Methods
ChIPChromatin was harvested as described. 17 ChIPs were performed using specific antibodies to ETO, HEB, ERG, FLI1 (Santa Cruz Biotechnology), H3K9K14ac, AML1-ETO, ETO, CBF-, RNAPII (Diagenode), RUNX1, and FLI1 (Abcam), and H4panAc (Millipore) and analyzed by quantitative PCR or ChIP-seq. Primers for quantitative PCR are described in supplemental Methods (available on the Blood Web site...